Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society

Henry N. Ginsberg1*†, Chris J. Packard2†, M. John Chapman3, Jan Borén4, Carlos A. Aguilar-Salinas 5,6, Maurizio Averna7, Brian A. Ference8, Daniel Gaudet 9, Robert A. Hegele 10, Sander Kersten11, Gary F. Lewis12, Alice H. Lichtenstein 13, Philippe Moulin 14, Børge G. Nordestgaard 15,16, Alan T. Remaley17, Bart Staels 18, Erik S.G. Stroes 19, Marja-Riitta Taskinen 20, Lale S. Tokgözoglu 21, Anne Tybjaerg-Hansen 22,23,24,25, Jane K. Stock26, and Alberico L. Catapano 27

1Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, West 168th Street, NY 10032, USA; 2Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK; 3Sorbonne University Endocrinology-Metabolism Division, Pitié-Salpêtrière University Hospital, and National Institute for Health and Medical Research (INSERM), 47 Hôpital boulevard, Paris 75013, France; 4Department of Molecular and Clinical Medicine, University of Gothenburg and Sahlgrenska University Hospital, Båå Stråket 5, Gothenburg 413 45, Sweden; 5Unidad de Investigación en Enfermedades Metabólicas y Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga 15, Belisario Dominguez Secc 16, Talpaín, Mexico City 14080, Mexico; 6Technologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Ave. Morones Prieto, Monterrey, Nuevo León 3000, Mexico; 7Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities, University of Palermo, Marina Square, Palermo 90133, Italy; 8Centre for Naturally Randomized Trials, University of Cambridge, Cambridge, UK; 9Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Center, Department of Medicine, Université de Montréal, ECOGENE, Clinical and Translational Research Center, and Lipid Clinic, Chicoitum, Hospital 305 Rue St Vallier, Chicoitum, Quebec G7H 5H6, Canada; 10Department of Medicine and Roberts Research Institute, Schulich School of Medicine and Dentistry, Western University, 1151 Richmond Street, London, Ontario N6A 3K7, Canada; 11Division of Human Nutrition and Health, Wageningen University, Wageningen, the Netherlands; 12Division of Endocrinology, Department of Medicine, Banting & Best Diabetes Centre, University of Toronto, Eaton Building, Room 12E248, 200 Elizabeth St, Toronto, Ontario M5G 2C4, Canada; 13Cardiovascular Nutrition, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, 711 Washington St Ste 9, Boston, MA 02111, USA; 14Department of Endocrinology, GHE, Hospitals Civils de Lyon, CarMen Laboratory, Inserm UMR 1060, CENS-ELI B, Univ-Lyon1, Lyon 69003, France; 15Department of Clinical Biochemistry, Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev Ringvej 75, Herlev 2730, Denmark; 16Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, Copenhagen DK-2200, Denmark; 17Lipoprotein Metabolism Section, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, 31 Center Dr Ste 10-7C114, Bethesda, MD 20892, USA; 18Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1061-EGID, Lille, France; 19Department of Vascular Medicine, Academic Medical Center, 1541 Kings Hwy, Amsterdam 1103, The Netherlands; 20Research Programs Unit, Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland; 21Department of Cardiology, Hacettepe University Faculty of Medicine, 06100 Sihhiye, Ankara, Turkey; 22Department of Clinical Biochemistry, Blegdamsvej, 9, Rigshospitalet, Copenhagen 2100, Denmark; 23Copenhagen General Population Study, Herlev and Gentofte Hospital, Herlev, Denmark; 24Copenhagen City Heart Study, Frederiksberg Hospital, Nordre Fasanvej, Frederiksberg 57 2000, Denmark; 25Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej, Copenhagen 3B 2200, Denmark; 26European Atherosclerosis Society, Måssans Gata 10, Gothenburg SE-412 51, Sweden; and 27Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano and IRCCS MultiMedica, Via Festa del Perdono 7, Milan 20122, Italy

* Corresponding author. Tel: +1 212 305 9562, Fax: +1 212 305 3213, Email: hng1@cumc.columbia.edu
†These authors contributed equally as first authors.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Recent advances in human genetics, together with a large body of epidemiologic, preclinical, and clinical trial results, provide strong support for a causal association between triglycerides (TG), TG-rich lipoproteins (TRL), and TRL remnants, and increased risk of myocardial infarction, ischaemic stroke, and aortic valve stenosis. These data also indicate that TRL and their remnants may contribute significantly to residual cardiovascular risk in patients on optimized low-density lipoprotein (LDL)-lowering therapy. This statement critically appraises current understanding of the structure, function, and metabolism of TRL, and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD). Key points are (i) a working definition of normo- and hypertriglyceridaemic states and their relation to risk of ASCVD, (ii) a conceptual framework for the generation of remnants due to dysregulation of TRL production, lipolysis, and remodelling, as well as clearance of remnant lipoproteins from the circulation, (iii) the pleiotropic proatherogenic actions of TRL and remnants at the arterial wall, (iv) challenges in defining, quantitating, and assessing the atherogenic properties of remnant particles, and (v) exploration of the relative atherogenicity of TRL and remnants compared to LDL. Assessment of these issues provides a foundation for evaluating approaches to effectively reduce levels of TRL and remnants by targeting either production, lipolysis, or hepatic clearance, or a combination of these mechanisms. This consensus statement updates current understanding in an integrated manner, thereby providing a platform for new therapeutic paradigms targeting TRL and their remnants, with the aim of reducing the risk of ASCVD.

**Graphical Abstract**

Formation of triglyceride-rich lipoprotein remnants and their role in atherogenesis. Metabolic scheme for the generation and clearance of triglyceride-rich lipoprotein remnant particles (A). In hypertriglyceridaemia, overproduction and inefficient lipolysis of both very low-density lipoprotein and chylomicrons lead to increased remnant formation. Triglyceride-rich lipoprotein remnants contribute to the initiation and progression of atherosclerotic lesions (B). Particle retention in the subendothelial space is followed by inflammation, cholesterol deposition, and macrophage foam cell formation.

**Keywords**

Triglycerides • Triglyceride-rich lipoproteins • Lipoprotein remnants • Cardiovascular disease • Residual risk

**Introduction**

For decades, triglycerides (TG) have been considered a putative risk factor for atherosclerotic cardiovascular disease (ASCVD).\(^1,2\) Despite mounting evidence from population and genetic studies, controversy persists. Much of this relates to two key questions: first, which is the culprit(s): TG molecules per se, TG-rich lipoproteins (TRL), or TRL remnants, and second, for TRL or their remnants, which components give rise to risk: cholesterol contained in these particles, other features, or both? Answers are essential to understand better the pathological consequences of raised TG levels, especially in the context of residual cardiovascular risk when other major factors, particularly low-density lipoprotein cholesterol (LDL-C), are optimally controlled. This statement aims to define what is known about the structure, function, metabolism, and atherogenicity of TRL and their remnants, and importantly, to identify targeted therapeutic approaches to address residual risk associated with elevated TG levels.

**Search strategy**

References (English language only) were identified through searches of PubMed for articles published from 2000 by the use of the terms ‘triglycerides’, ‘lipoprotein remnants’, ‘triglyceride-rich lipoproteins’, in combination with the terms ‘cardiovascular disease’,
Triglycerides, triglyceride-rich lipoproteins, and remnants: definitions and clinical relevance

Triglycerides are an efficient means of storing excess energy, mainly in adipose tissue. In the blood, TG and cholesteryl esters (CE) circulate within the core of spherical lipoproteins, covered with a monolayer ‘shell’ of phospholipids and free cholesterol, with apolipoproteins stabilizing the structure. Apolipoprotein (apo) B is the major structural protein in TRL, present as either apoB100, made in the liver, or a truncated form, apoB48, made in the intestine. These isoforms, rather than size or density, best define the TRL class. Very low-density lipoproteins (VLDL), made in the liver, contain apoB100 and are metabolized to VLDL remnants, intermediate-density lipoproteins (IDL), and LDL. Chylomicrons, made in the intestine, are larger and contain apoB48, and are also metabolized to remnant particles but not to IDL and LDL (Figure 1). The intestine also secretes apoB48-containing VLDL-sized particles.\(^3\)

TRL decrease in size during lipolysis; concomitantly, the core content of TG decreases and CE increases due to cholesteryl ester transfer protein (CETP)-mediated exchange of TRL–TG for LDL- and high-density lipoprotein (HDL)-CE. During lipolysis apoB remains with the TRL on which it was secreted. With one apoB molecule per particle, apoB concentration is thus a measure of particle number. Other apolipoproteins (particularly apoCs) transfer mainly to HDL during lipolysis. The spectrum of apoB100- and apoB48-containing remnants varies with plasma TG levels (Figure 1). At optimal levels (<1.2 mmol/L or <100 mg/dL),\(^4\) efficient lipolysis results in limited accumulation of remnant
particles, predominantly in the small VLDL and IDL size range. At higher TG levels (e.g. ≥3.0 mmol/L or ≥260 mg/dL), increased secretion and impaired lipolysis result in the substantial accumulation of chylomicron and VLDL remnants. 

Remnant lipoproteins are enriched in cholesterol (both free and esterified) and are depleted in apoC proteins and enriched in apoE (Figure 2).5–7 The remnant lipoproteins seen in type III hyperlipidaemia (‘dysbetalipoproteinaemia’ or ‘remnant’ hyperlipidaemia) are an extreme example of this particle type. Remnants are cleared directly by the liver or converted to IDL and LDL. In most people, remnant lipoproteins (and TRL in general) are highly heterogeneous (Figure 1).3,6–8 Thus, defining which features confer atherogenicity is challenging.

Extreme elevations of plasma TG levels (>10 mmol/L or >880 mg/dL) increase the risk for acute pancreatitis10–13 but it is less widely appreciated that fasting levels from as low as ~1.2 mmol/L (~100 mg/dL) can be associated with a cluster of metabolic abnormalities that include accumulation of TRL and remnants.13 as well as increased cardiovascular disease events15,16 (Figure 1). These lipoprotein particles become more abundant as TG concentrations increase from ‘borderline’ to ‘moderate’, ‘severe’, and ‘extreme’. Working consensus definitions for these categories of hypertriglyceridaemia are given in Box 1.4,14,17–23

Over the past three decades, epidemiologic and genetic evidence has accumulated to support the concept that elevated levels of plasma TG, TRL, and TRL remnants are causally related to an increased risk of ASCVD-related events—myocardial infarction (MI), stroke, and aortic valve stenosis—and all-cause mortality.1,2,17,19,20,24–28 Mendelian randomization studies focused on variants in the genes encoding apoAV, apoCIII, lipoprotein lipase (LpL) and the angiopoietin-like proteins 3, 4, and 8 (ANGPTL3, ANGPTL4, and ANGPTL8) have been highly informative.29–35 Currently, given that no clear signal indicates which features of TRL give rise to risk, and recognizing the need for further study to identify the best index of ASCVD risk, plasma TG levels are a reasonable surrogate. The increase in absolute risk is greatest for MI (approximately four-fold at TG levels >5 mmol/L or >440 mg/dL vs. <1 mmol/L or <88 mg/dL), and less for ischaemic stroke and aortic stenosis (Figure 3).11,17,27,28

Furthermore, elevated plasma TG levels (with the accumulation of TRL and remnant particles) are related not only to subclinical atherosclerosis and vascular inflammation independently of LDL-C in statin-naive, apparently healthy subjects, but also equally to residual cardiovascular risk among statin-treated patients, especially those with diabetes mellitus.2,20,36–38

Consensus key points

- Accumulating evidence from epidemiologic and genetic studies is consistent with a causal relationship between ASCVD risk and elevated plasma levels of TG, TRL, and TRL remnants.
- TRL and TRL remnants accumulate in the plasma at fasting TG levels >1.2 mmol/L (>100 mg/dL).
- At fasting TG levels >1.7 mmol/L (>150 mg/dL), there is consensus that ASCVD risk becomes clinically relevant.4,20,38 TG levels >10 mmol/L (>880 mg/dL) confer a high risk of pancreatitis with the risk increasing significantly when TG levels are >20 mmol/L.

What causes remnant lipoproteins to accumulate?

What are the major metabolic defects in hypertriglyceridaemia?

The primary role of TRL is to transport TG to adipose tissue for storage and to skeletal and cardiac muscle for energy production. The metabolism of apoB-containing lipoproteins is integral to these functions44–46 (Figure 4), with regulation of the assembly, secretion, and clearance of TRL discussed below.

Metabolism of triglyceride-rich lipoproteins and their remnants

Key questions

- What are the major metabolic defects in hypertriglyceridaemia?
- What causes remnant lipoproteins to accumulate?

What factors regulate the assembly and secretion of triglyceride-rich lipoproteins?

Hormones, nutrients, neural signals, and multiple enzymes and proteins, including CD36, FATP4, FABP1, FABP2, MTP, apoAIV, apoCIII, perilipin, and SAR1B, regulate the assembly and secretion of chylomicrons.37 These factors direct lipids to storage in cytosolic lipid droplets in enterocytes, or oxidative breakdown, or incorporation into pre-chylomicron particles in the endoplasmic reticulum, which undergo expansion to full-sized chylomicrons.48 The availability of apoB48—regulated by insulin, gut peptides, neural networks, and nutrient signals [fatty acids (FA) and glucose]—determines the rate of chylomicron formation. Increased numbers of small chylomicrons are secreted by individuals with insulin resistance.49,50 Intestinal lipid droplets appear to act as temporary lipid stores, modulating the release and size of chylomicrons following meals.51 Changes in intestinal lymphatic flow may be important in determining how rapidly dietary TG are delivered as TG–FA to peripheral tissues.52

For VLDL, the chronic effects of excess nutrients and insulin resistance are most important, increasing hepatic secretion of larger particles.53,54 VLDL assembly and secretion are upregulated by (i) the delivery of FA released from insulin-resistant adipocytes, (ii) the increased delivery of remnant TG–FA to the liver due to reduced peripheral lipolysis of chylomicron and VLDL–TG, and (iii) the increased de novo lipogenesis55 (Figure 4).

What factors regulate the lipolysis of triglyceride-rich lipoproteins?

Cleavage of TRL involves two interrelated processes, lipolysis of TG by LpL, and hepatic clearance of remnants. Lipoprotein lipase-mediated hydrolysis of TG was thought to be a relatively simple process regulated by tissue LpL expression, and the content of apoCII (an activator) and apoCIII (an inhibitor) on TRL. However, accumulating
Figure 2 Physicochemical characteristics of remnant lipoproteins. (A) Remnant lipoproteins are partially lipolysed products of lipoprotein lipase action. They have a triglyceride-depleted core and are enriched in cholesteryl esters. The main structural protein is apolipoprotein (apo)B48 in chylomicron remnants and apoB100 in very low-density lipoprotein remnants. A typical normal-sized low-density lipoprotein particle is shown for comparison. (B) Comparison of the cholesterol/apoB molar ratios in remnant-like particles isolated by immunoaffinity gel from the plasma of fasting subjects with Type III dyslipoproteinaemia, in which remnant particles accumulate, or borderline or moderately elevated triglyceride levels (data extracted from ref5). Only traces of remnant particles were detected in subjects with borderline elevated triglyceride levels. apo, apolipoprotein; CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; HSPG, heparan sulphate proteoglycans; LDLr, low-density lipoprotein receptor; LRP1, low-density lipoprotein receptor-related protein 1; mol, molecules; RLP, remnant-like particle; RLP-C, remnant-like particle cholesterol; TG, triglyceride; TRL, triglyceride-rich lipoproteins.
Box 1 Consensus definitions of normo- and hypertriglyceridaemia

| Category        | Triglyceride level mmol/L (mg/dL) |
|-----------------|-----------------------------------|
| Optimal         | <1.2 (<~100)                      |
| Borderline      | 1.2–1.7 (100–150)                 |
| Moderately elevated | 1.7–5.7 (150–500)             |
| Severe          | 5.7–10.0 (500–880)                |
| Extreme         | >10 (>880)                        |

Plasma TG varies over a wide range in the population, and as levels rise, the risk of atherosclerotic cardiovascular disease increases continuously. For this reason, as with LDL-C, it is inappropriate to use classical percent thresholds (5th, 95th percentile) to define ‘normal’ and ‘abnormal’. The cut-points here are derived from previous guidelines, epidemiological surveys and studies of TG metabolism. Extreme elevation is the threshold for high risk of acute pancreatitis. The division between ‘optimal’ and ‘borderline’ is based on recommendations from previous guidelines and the findings that remnant populations begin to be detectable using the remnant-like particle assay above this level and small, dense LDL formation is concomitantly enhanced. These cut-points are arbitrary but in the view of the Consensus Panel may serve as a working definition that has clinical utility. There is no distinction by gender.\(^{14,17–23}\)

LDL-C, low-density lipoprotein cholesterol; TG, triglyceride.

Evidence indicates greater complexity, involving apoAV, ANGPTL3, 4 and 8, lipase maturation factor-1 (LMF1), and glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein (GPIHBP1)\(^{18,56}\) (Figure 4). Complete loss-of-function (LOF) mutations in genes encoding several of these proteins can cause severe hypertriglyceridaemia (LpL, apoCII, apoAV, LMF1, and GPIHBP1) or hypolipidaemia (apoCIII, ANGPTL3, and ANGPTL4). Heterozygous LOF has also been identified in some patients with polygenic severe hypertriglyceridaemia.\(^{13,57}\)

Two of these proteins, apoCIII and ANGPTL3, have emerged as key therapeutic targets. ApoCIII is a major determinant of how efficiently TG are cleared from the plasma.\(^{58}\) Loss-of-function variants of APOC3 that result in reduced synthesis of the protein are associated with absent or low circulating apoCIII levels, increased efficiency of TG removal from TRL, and lower plasma TG levels,\(^{59,60}\) whereas increased apoCIII levels, as seen in insulin resistance and obesity, result in reduced clearance and higher plasma TG\(^{51–53}\) (Figure 4). ANGPTL3, 4, and 8 are inhibitors of LpL and play important roles in targeting chylomicrons and VLDL to white adipose tissue or skeletal muscle, depending on nutritional and hormonal status at any time.\(^{45}\) Loss-of-function variants in ANGPTL3 have been associated with reduced plasma levels of TG, LDL-C, and HDL-C.\(^{32,64,65}\)

Which factors regulate the generation and clearance of chylomicron and very low-density lipoprotein remnants?

Remnant formation is enhanced by overproduction of TRL or by genetic or physiological factors that limit lipolysis, or both. At moderately elevated plasma TG levels, there is increased secretion of large TG-enriched VLDL and chylomicrons from the liver and small intestine that, when combined with suboptimal LpL action in obesity, insulin resistance, and/or diabetes mellitus, results in remnant accumulation.\(^{58}\) Variants in the LpL gene that cause partial LOF of the LpL enzyme, or in other genes affecting LpL activity, also lower the rate of TG removal from VLDL and chylomicrons, resulting in elevated plasma TG levels and remnant accumulation even when TRL secretion is normal (Figure 5).\(^{5,44,66}\) The absence of lipolysis (i.e. complete LPL deficiency) results in the extreme elevation of large ‘nascent’ TRL without any concomitant increase in remnants;\(^{16,67,68}\) here, pancreatitis rather than ASCVD is the major risk.

Metabolic processing of newly secreted TRL by LpL generates a partially lipolysed heterogeneous population of remnant particles. Some of the apoB100 remnants are efficiently further lipolysed by LpL and hepatic lipase (HL) to LDL; they can be viewed as ‘transient’ remnants. Other apoB100 remnants, and all apoB48 remnants, undergo remodelling that renders them resistant to further lipolysis, remaining in the VLDL–IDL density range as ‘end-product’ remnants, until they are removed directly from the circulation by the liver. The underlying basis for these alternative pathways of TRL remnant metabolism is not well understood (Figure 5). The longer a remnant remains in the circulation, the more it becomes enriched with CE; the cholesterol content in these end-product remnants can exceed 7500 molecules per particle (vs. 2000–2700 in LDL). Several factors, including activating or inhibitory apolipoproteins (apoCIII and apoCII, respectively) on the TRL surface, and LpL availability, influence residence time in the circulation and the potential entry and retention of remnants within the arterial subendothelial space.\(^{5}\)

As stated above, all chylomicron remnants and variable amounts of VLDL remnants undergo direct hepatic clearance (Figures 2 and 4), mainly involving the LDL receptor, although studies in mice suggest putative roles for LDL receptor-related protein 1 and heparan sulphate proteoglycans (particularly syndecan 1).\(^{69,70}\) For chylomicron remnants, functional apoE on the particle is required (apoB48 is not a ligand).\(^{71}\) In type III hyperlipidaemia, patients are homozygous for the APOE2 variant that lacks the ability to bind to lipoprotein receptors; however, only a minority develop ‘remnant’ dyslipidaemia, implying...
that secondary acquired or inherited factors (e.g., insulin resistance) are needed to increase VLDL and chylomicron secretion or impair lipolysis, resulting in hyperlipidaemia. An identifying feature is a grossly elevated cholesterol/TG ratio in TRL, due to marked accumulation of VLDL and chylomicron ‘end-product’ remnants highly enriched in cholesterol (up to 10,000 molecules per particle)\(^5\) (Figure 5). The elevated ASCVD risk in this dyslipidaemia is \textit{prima facie} evidence for the role of remnant lipoproteins in atherogenesis, as LDL levels are typically low.\textsuperscript{72}

**Figure 4** Overview of apolipoprotein B lipoprotein metabolism. During absorption of fat from the diet, chylomicrons are generated by the enterocytes in the small intestine, travel via lymphatics, and appear in the bloodstream. Lipidation of a primordial apolipoprotein (apo) B48-containing particle (apoB48, a truncated form of apoB100 made solely in the intestine) is mediated by microsomal triglyceride transfer protein using triglyceride synthesized from absorbed fatty acids. In a similar assembly process, a large triglyceride-rich, apoB100-containing very low-density lipoprotein (VLDL)\(_1\) is made in the liver using a variety of sources for triglyceride synthesis—\textit{de novo} lipogenesis, fatty acids released from intracellular storage droplets, free fatty acids taken up from the circulation after their release from adipose tissue, and triglyceride fatty acids present in VLDL chylomicron remnants. Chylomicrons and VLDL\(_1\) (and to an extent VLDL\(_2\)) compete for the same lipolytic mechanism. Lipoprotein lipase is anchored to the luminal surface of the capillary endothelium in skeletal muscle and adipose tissue by glycosphingolipid-anchored high-density lipoprotein-binding protein-1. This enzyme hydrolyzes triglyceride in the core of the particle releasing fatty acids into the underlying tissue bed. Lipase maturation factor 1 is essential for the secretion of functional lipase from adipose tissue and muscle. ApoCII is an activator (essential cofactor) of lipoprotein lipase, whereas apoCIII is an inhibitor of the enzyme and of remnant particle uptake. The angioptoin-like proteins 3, 4, and 8 (ANGPTL3, 4, 8) have a tissue-specific role in modifying (inhibiting) lipoprotein lipase action, whereas apoAV increases lipoprotein lipase-mediated lipolysis. Lipolysis of chylomicrons leads to the formation of remnant particles, which are cleared by the liver via the low-density lipoprotein receptors and, based on mouse studies, the low-density lipoprotein receptor-related protein 1. Likewise, VLDL\(_1\) is delipidated to VLDL\(_2\), remnants, and intermediate-density lipoproteins, which are either removed by liver receptors or converted to low-density lipoprotein as the final product. Smaller VLDL\(_2\) is also made by the liver and can be delipidated to intermediate-density lipoprotein and low-density lipoprotein (for more detail see refs\textsuperscript{43–45}). It should be noted that lipolysis of both chylomicrons and VLDL in adipose tissue and skeletal muscle is neither equally divided nor randomly apportioned but is determined by insulin mediated regulation of lipoprotein lipase in each tissue, with insulin stimulating lipoprotein lipase in adipose tissue and inhibiting it in skeletal muscle. In addition, ANGPTL3 and ANGPTL8 inhibit lipoprotein lipase activity in skeletal muscle in the fed state and ANGPTL4 inhibits lipoprotein lipase activity in white adipose tissue during fasting.\textsuperscript{45} FFA, free fatty acids; GPIHBP1, glycosphingolipid-anchored high-density lipoprotein-binding protein-1; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LDLr, low-density lipoprotein receptor; LMF1, lipase maturation factor 1; LRP1, low-density lipoprotein receptor-related protein 1; MTP, microsomal triglyceride transfer protein; VLDL, very low-density lipoprotein.

**Figure 5** Overview of primary and secondary lipoprotein metabolism. ApoB100 synthesis and VLDL1 Lipoprotein metabolism is mediated by a primordial apolipoprotein (apo) B48-containing particle (apoB48, a truncated form of apoB100 made solely in the intestine) that undergoes lipidation. B100 synthesis Lipoprotein lipase is anchored to the luminal surface of the capillary endothelium in skeletal muscle and adipose tissue by glycosphingolipid-anchored high-density lipoprotein-binding protein-1. This enzyme hydrolyzes triglyceride in the core of the particle releasing fatty acids into the underlying tissue bed. Lipase maturation factor 1 is essential for the secretion of functional lipase from adipose tissue and muscle. ApoCII is an activator (essential cofactor) of lipoprotein lipase, whereas apoCIII is an inhibitor of the enzyme and of remnant particle uptake. The angioptoin-like proteins 3, 4, and 8 (ANGPTL3, 4, 8) have a tissue-specific role in modifying (inhibiting) lipoprotein lipase action, whereas apoAV increases lipoprotein lipase-mediated lipolysis. Lipolysis of chylomicrons leads to the formation of remnant particles, which are cleared by the liver via the low-density lipoprotein receptors and, based on mouse studies, the low-density lipoprotein receptor-related protein 1. Likewise, VLDL\(_1\) is delipidated to VLDL\(_2\), remnants, and intermediate-density lipoproteins, which are either removed by liver receptors or converted to low-density lipoprotein as the final product. Smaller VLDL\(_2\) is also made by the liver and can be delipidated to intermediate-density lipoprotein and low-density lipoprotein (for more detail see refs\textsuperscript{43–45}). It should be noted that lipolysis of both chylomicrons and VLDL in adipose tissue and skeletal muscle is neither equally divided nor randomly apportioned but is determined by insulin mediated regulation of lipoprotein lipase in each tissue, with insulin stimulating lipoprotein lipase in adipose tissue and inhibiting it in skeletal muscle. In addition, ANGPTL3 and ANGPTL8 inhibit lipoprotein lipase activity in skeletal muscle in the fed state and ANGPTL4 inhibits lipoprotein lipase activity in white adipose tissue during fasting.\textsuperscript{45} FFA, free fatty acids; GPIHBP1, glycosphingolipid-anchored high-density lipoprotein-binding protein-1; IDL, intermediate-density lipoprotein; LDL, low-density lipoprotein; LDLr, low-density lipoprotein receptor; LMF1, lipase maturation factor 1; LRP1, low-density lipoprotein receptor-related protein 1; MTP, microsomal triglyceride transfer protein; VLDL, very low-density lipoprotein.

Hepatic clearance of VLDL remnants is mediated by either apoB100 or apoE through receptor-dependent and receptor-independent pathways.\textsuperscript{7,17,71,73} 25–75% of these particles are removed directly rather than converted to LDL. Which factors determine the fate of a remnant particle (in the VLDL or IDL density range) remains incompletely defined, although apoCII inhibits whereas apoE and possibly HL facilitate hepatic remnant uptake.\textsuperscript{7,73} In mice, apoCII impacts plasma TG levels and remnant accumulation when LpL activity is reduced, but not when normal.\textsuperscript{75} Additional
studies in mice suggest that endothelial lipase may play a role in remnant removal independent of LpL and LDL receptors.76

The preceding discussion illustrates the difficulty inherent in defining remnants. Identifying a proteomic or lipidomic signature specific for a sub-population of TRL that contributes to atherogenesis is crucial; lacking this, a looser concept is necessary, as discussed below.

Why do fasting plasma triglyceride levels vary widely?

Plasma TG levels range from 0.33 to 120 mmol/L (30 to 10 000 mg/dL)13,17 (Figure 6), reflecting variability in the rates of secretion and clearance of TG and apoB in VLDL and chylomicrons.61,77

With borderline to moderately elevated plasma TG, overproduction is typically the main contributor, whereas reduced LpL-mediated lipolysis of TG is the dominant abnormality when plasma TG is severely elevated. The two- to four-fold range of secretion and several-fold range of clearance underlie the observed population variability.

Another reason for the wide range of plasma TG levels is variability in the non-fasting (postprandial) state. Whether fasting or non-fasting plasma TG levels provide a better index of ASCVD risk is pertinent;78,79 the role of postprandial lipaemia in atherosclerosis is discussed in Box 2.3,25,80–92

Consensus key points

- Chylomicrons and VLDL (TRL) are assembled in the small intestine and liver, respectively, and transport TG and cholesterol in the circulation.
- Plasma levels of TRL are determined by the rate of production, the efficiency of removal of TG content by lipolysis, and hepatic clearance.
- Several enzymes, lipid transfer proteins, and the lipid and protein composition of TRL and remnants all contribute to the regulation of lipolysis and hepatic clearance of these lipoproteins.
- In severe hypertriglyceridaemia, a reduced TRL clearance rate is the dominant metabolic abnormality.
- Partial removal of TG from chylomicrons or VLDL creates remnants. Remnant levels depend on the extent of lipolysis, conversion of VLDL remnants to LDL, and the efficiency of hepatic removal of both VLDL and chylomicron remnants.
- Remnant particles may contain up to four-fold greater cholesterol content per particle than LDL.
Does abnormal triglyceride-rich lipoprotein metabolism impact other lipoprotein classes?

As LDL is the terminal product of the VLDL delipidation and remodelling cascade, changes in VLDL metabolism impact LDL structure, function, and metabolism. Plasma TG modifies LDL size and composition,66,93 higher levels result in small, dense LDL generated via CETP-mediated lipid exchange of LDL-CE with TRL–TG and subsequent lipolysis. These particles may be enriched in bioactive inflammatory lysolipids and are more likely to be retained in arterial atherosclerotic lesions because of their longer plasma residence time.66,93

Circulating HDL are highly heterogeneous in their physicochemical properties and biological activities, reflecting the complexity of metabolic processes underlying their production, intravascular remodelling, and catabolism.2,94–96 Hypertriglyceridaemia leads to significant perturbations in HDL metabolism, and in direct consequence, to subnormal HDL-C levels.2,94,95,97,98 This involves major modification of the HDL proteome and lipoprotein,99,100 resulting in attenuated vasculoprotective functions including reverse cholesterol transport, inhibition of oxidation, and anti-inflammatory activities.96,101,102 The relevance of these alterations to increased ASCVD risk in hypertriglyceridaemia is unclear due to physiologically interrelated pathways.

Consensus key points

• Changes in VLDL metabolism impact the structure, composition, metabolism, and function of LDL and HDL particles.
• Hypertriglyceridaemia favours the formation of small, dense LDL with potentially increased atherogenicity and smaller, denser HDL particles with a perturbed lipoprotein and proteome and defective vasculoprotective functions. The degree to which these alterations contribute to cardiovascular risk is unclear.
Intestinal lipoprotein metabolism is more complex than previously recognized. Chylomicron production is linked to a taste–gut–brain axis. In both fasting and postprandial states, apoB48-containing particles are secreted not only as chylomicrons but also as smaller TRL particles resembling VLDL.

Box 2  Postprandial lipid metabolism

Supporting refs

• Most individuals are in a postprandial state, ingesting several fat-rich meals during the day. Plasma TG levels peak after bedtime and the nadir is in the early morning after an overnight fast. In a ‘real-world’ setting, random non-fasting (postprandial) TG is on average 20–25% higher than fasting values. This difference is, however, determined significantly by the fasting value.

• Fasting plasma TG is strongly predictive of TG responses after eating.

• Population and genetic studies identify non-fasting (postprandial) hypertriglyceridaemia, occurring 8 h or more after a meal, as an important but neglected risk factor for premature ASCVD.

• Postprandial accumulation of TRL typically detected as area under the curve for TG, is driven by overproduction and/or decreased catabolism of these particles. Predisposing genetic variations and clinical conditions such as obesity and insulin resistance often underlie such accumulation.

• Large TRL are not atherogenic, in contrast to cholesterol-rich remnants that are formed after removal of TG from TRL by lipoprotein lipase-mediated lipolysis.

• Clinical recognition of postprandial hypertriglyceridaemia is hampered by technical difficulties and the lack of established clinical protocols for its characterization.

• While ~80% of the rise in TG levels after a fat-load meal is due to intestinally derived B48-containing lipoproteins, apoB100-containing VLDL account for most (~80%) of the increase in particle number.

• Intestinal lipoprotein metabolism is more complex than previously recognized. Chylomicron production is linked to a taste–gut–brain axis. In both fasting and postprandial states, apoB48-containing particles are secreted not only as chylomicrons but also as smaller TRL particles resembling VLDL.

ASCVD, atherosclerotic cardiovascular disease; TG, triglyceride; TRL, triglyceride-rich lipoproteins; VLDL, very low-density lipoprotein.

Role of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease

Key questions

• How are elevated TRL linked to cardiovascular risk?

• Do we need new tools to evaluate cardiovascular risk associated with hypertriglyceridaemia?

How do triglyceride-rich lipoproteins and remnants exert atherogenic effects at the arterial wall?

While LDL-C is an established major causal factor for ASCVD,93,103,104 the causality of TG, TRL, or TRL remnants for ASCVD is contentious.17,36,105–107 Partly, this relates to variable TRL composition (Figures 2 and 4 and Box 3).2,7,17,44,73,95,108–111 While there is no evidence that TG directly exert atherogenic effects,17 free FA liberated during lipolysis of TRL–TG (in the subendothelial space or at the endothelial surface) can exert proinflammatory effects on endothelial cells and monocyte-derived macrophages.112–114 This is evident with saturated FA, but not polyunsaturated forms (e.g. omega-3 free FA).112,115 Lipid-loaded foam cells and smooth muscle cells in lesions, abundant sources of LpL, promote endothelial activation and permeability (Box 4).112–119 LpL in arterial macrophages may also directly promote atherogenesis.120

The TRL delipidation cascade generates subpopulations (remnants, IDL) differing in atherogenic potential.2,3,5,44,73,86,93,121 Particles below ~70 nm diameter (which excludes most newly secreted, non-lipolysed chylomicrons and very large VLDL) traverse the endothelium by active transcytosis93 and are retained in the subendothelial layer of the artery wall, contributing to lesion initiation and progression mainly by mechanisms involving cholesterol deposition, inflammation, and prothrombotic effects (Figure 7 and Box 4).2,3,7,17,25,36,73,108–119,122 Remnant particles in the small VLDL and IDL range, with at least 30% cholesterol by weight, may contain up to four-fold more cholesterol molecules than an LDL particle (up to 10 000 vs. 2000–2700 cholesterol molecules per lipoprotein particle, respectively).123,124 VLDL and remnants are also enriched in apoE and apoCIII, both implicated in binding and retention in the artery wall.5,71,125 These factors enhance remnant cholesterol deposition in the plaque;71,126,127 indeed, unlike LDL, remnant particle entry exceeds efflux.127–129 Similar to LDL, denaturation of cholesterol-rich remnant particles in the subendothelial environment may give rise to cholesterol microdomains130 favouring the formation of cholesterol monohydrate crystals.93,131,132 Crystal formation may also occur upon VLDL or remnant uptake by macrophages, with activation of the NLRP3 inflammasome and an inflammatory response.130,133–135 Cholesterol crystals induce macrophage apoptosis, with major implications for plaque instability and rupture.136 Indeed, cholesterol crystals are typical of the
TRL, their remnants, and ASCVD

**Box 3** The proteome and lipidome of triglyceride-rich lipoproteins and their remnants

- The proteomes of TRL and remnant particles contain a single copy of either apoB48 or apoB100, together with other, smaller apolipoproteins (CII, CII, CI, AIV, AV, E, and traces of AI and II) and ANGPTL-3, -4, and -8. The proteome of remnant particles is enriched in apoE and apoCIII.

- The lipidomes of TRL and their remnants undergo dynamic intravascular metabolic remodelling, reflecting the activities of LpL, HL, CETP, and PLTP. Remnant particles are enriched in cholesteryl esters and deficient in TG (Figure 2). Proteomic components modulate rates of lipolysis, cholesteryl ester enrichment, and hepatic clearance of TRL and remnants.

- In atherogenic dyslipidaemia (TG levels >2.3 mmol/L or >200 mg/dL), the lipidome of the VLDL + IDL fraction (density <1.019 g/mL) comprises >20 distinct lipid classes, representing >500 individual molecular species (Meikle PJ, and Chapman MJ, unpublished data). Among the fasting apoB-containing lipoproteins under dyslipidaemic conditions, TRL and their remnants are the predominant plasma transporter of neutral lipids (triacylglycerols, dacylglycerols, and cholesteryl esters): 28, 110, and 190 nmol/mL plasma, respectively. Specific phospholipids (phosphatidylethanolamine and phosphatidylinositol; 5.8 and 10.1 nmol/mL plasma, respectively), and ceramides (0.9 nmol/mL plasma).

- Based on these findings, is there a lipidomic signature for remnant particles? And if so, is this specific to apoB48, rather than apoB100-containing remnants?

**Box 4** Putative effects of triglyceride-rich lipoproteins and their remnants on vascular wall biology and their relevance to atherothrombosis

- Acute elevation of TRL and their remnants in the postprandial phase induces impaired vasodilatation, upregulates production of proinflammatory cytokines, enhances an endothelial inflammatory response, and upregulates expression of vascular cell adhesion molecule-1 and monocyte activation. This involves both direct and indirect mechanisms.

- Lipolytically released saturated fatty acids and phospholipids containing oxidized fatty acids activate toll-like receptors of subendothelial macrophages, producing reactive oxygen species (ROS) and proinflammatory lipids and proteins.

- TRL-associated apolipoprotein (apo) CIII activates the NLRP3 inflammasome in human monocytes by inducing an alternative NLRP3 inflammasome via caspase-8 with dimerization of toll-like receptors 2 and 4. This process involves production of ROS. ApoCIII-activated human monocytes impede endothelial regeneration in vivo.

- TRL and their remnants are implicated in plaque rupture and thrombus formation via redox-sensitive mechanisms, tissue factor secretion from the endothelium, and stimulation of monocytes and thrombin generation. Coagulation factors VII and X are specifically bound and transported by chylomicrons and very low-density lipoproteins.

Angiopoietin-like proteins (angioptin-like proteins 3, 4, B: apo, apolipoprotein; CETP, cholesteryl ester transfer protein; HL, hepatic lipase; IDL, intermediate-density lipoprotein; LpL, lipoprotein lipase; PLTP, phospholipid transfer protein; TGL, triglyceride; TRL, triglyceride-rich lipoproteins; VLDL, very low-density lipoprotein.

remnant cholesterol levels are causally related to whole body low-grade inflammation, in contrast to LDL-C. Recently, the PESA (Progression of Early Subclinical Atherosclerosis) study reported a significant association of vascular inflammation with TG levels >1.7 mmol/L.

Given the greater abundance of LDL particles (estimated particle numbers for LDL are 3–10 greater than for TRL in most individuals), and longer plasma residence time (on average, 2.5–3.5 days for LDL vs. 4–13 h for chylomicrons and VLDL in subjects with raised TG), then LDL is clearly the primary atherogenic lipoprotein target for ASCVD prevention. This comparison of numbers of remnant particles vs. LDL is an approximation given current limitations in our ability to precisely define the nature of remnant particles. Published studies suggest that up to 30% of the cholesterol load in apoB-containing lipoproteins can be transported by remnant particles when calculated as the cholesterol content of the VLDL + IDL fraction. In this context, it should be noted that TG-rich particles...
secreted from the intestine and liver become ‘transient’ remnants very soon after entering the plasma compartment due to their exposure to remodelling enzymes, metabolically active apolipoproteins, and lipid transfer factors and hence are included in the overall remnant particle count.

When considering the clinical relevance of particle abundance, it is noteworthy that despite the predominance of LDL particle numbers in fasting and postprandial states, the relative danger of ‘remnants’ cannot simply be equated with their particle number, as multiple factors are implicated in a comparison of the relative atherogenicity of these two sets of particles. Such factors include plasma residence time, cholesterol load, rates of penetration and retention in the arterial intima, susceptibility to modification in situ, rates of uptake in macrophages, and propensity to form proinflammatory foam cells. Thus, even with uncertainty regarding the exact proportion of cholesterol carried in remnants, in part due to methodological issues, the long duration of elevated levels during the postprandial period (>8 h) results in the arterial wall being extensively exposed to remnant particles. Both apoB48- and apoB100-containing remnant particles have been identified in human atherosclerotic lesions.

Taken together, there is evidence for interactive and complementary mechanisms for apoB48- and apoB100-containing remnants in atherogenesis. Since first proposed, increased levels of intestinal-derived postprandial lipoproteins have been increasingly recognized as key players in the development of ASCVD.
composition after dietary fat absorption.\textsuperscript{150} Fasting/non-fasting plasma TG measurement provides a basis for guideline thresholds for hypertriglyceridaemia.\textsuperscript{13,126} Non-fasting TG is equivalent, if not superior, to fasting TG in assessing potential ASCVD risk.\textsuperscript{78,79} If TRL promote plaque development and inflammation predominantly due to their cholesterol content (either fasting or non-fasting), then TRL cholesterol might be a superior index of ASCVD risk, either assayed directly or estimated (Box 5).\textsuperscript{66,153,154} Estimation of VLDL cholesterol concentration by nuclear magnetic resonance (NMR) spectroscopy analysis was recently proposed as a surrogate for remnant lipoproteins.\textsuperscript{155} Prospective evaluation of its relationship to MI risk concluded that VLDL cholesterol influenced ASCVD risk similarly to LDL-C, although as suggested, further validation of NMR-based particle measurement is needed before wider adoption.\textsuperscript{146}

Non-HDL-C, which by definition includes the cholesterol in LDL-C, remnants, and lipoprotein(a).\textsuperscript{79,156} is a simple, robust index of the total concentration of potentially atherogenic particles in the circulation. Widely recommended by guidelines, non-HDL-C highlights elevated remnants in type 2 diabetes mellitus.\textsuperscript{20,157} Subtracting directly measured LDL-C from non-HDL-C provides a crude estimate of remnant cholesterol content\textsuperscript{146} but includes cholesterol in TRL not yet processed to remnants. Assays that specifically measure the cholesterol content of remnant particles have revealed significant associations with ASCVD.\textsuperscript{17,84} These include the remnant-like particle assay\textsuperscript{68,158,159} and a direct assay of TRL cholesterol. Among emerging approaches, assays of total apoB, apoB100, and apoB48 would offer direct measures of TRL particle number. In addition, several studies have indicated that TRL ceramide species may be predictive of cardiovascular events and mortality.\textsuperscript{68,160–162} (Box 5). Finally, readers should note that the proposed cut-points (Box 1) reflect current knowledge; further studies are necessary to more accurately relate each category of hypertriglyceridaemia to risk for ASCVD and/or pancreatitis. It is reasonable, therefore, to continue to use TG, which is routinely measured in all clinical laboratories, as a surrogate biomarker.

**Strategic approaches to lowering of triglyceride-rich lipoproteins and remnants for atherosclerotic cardiovascular disease prevention**

**Key questions**

- Are the proatherogenic mechanisms of TRL sufficiently understood for therapeutic targeting in ASCVD patients with residual risk?
- What are the optimal strategies for reducing ASCVD risk in hypertriglyceridaemia?
- Are currently available therapeutics targeting pathways that will result in reduction of cardiovascular risk? What does the future offer?

Available and novel therapies that target TG metabolism can reduce TRL plasma concentration but need to be evaluated individually for impact on atherogenic lipoproteins. Baseline TG level (fasting or non-fasting), as a reflection of the underlying metabolic abnormality (Figure 6), as well as concomitant medications, especially LDL-lowering drugs, may also influence the potential impact of any therapy on ASCVD outcomes. For example, fibrates effectively lower TG across the range of TG levels but only modestly reduce apoB levels. Their effects on LDL-C differ between moderate hypertriglyceridaemia (LDL-C is decreased or shows no change) and severe hypertriglyceridaemia (LDL-C is increased, albeit from a low baseline level).\textsuperscript{163,164}

Guideline-recommended first steps for managing hypertriglyceridaemia are diet modification and weight loss. Dietary goals include (i) avoiding highly refined carbohydrate foods;\textsuperscript{4,165} (ii) incorporating seafood, particularly fatty fish;\textsuperscript{166} (iii) increasing fibre-rich foods (fruits, vegetables and whole grains);\textsuperscript{4} (iv) avoiding excess alcohol;\textsuperscript{167} and (v) substituting mono- and polyunsaturated fat (mostly from plant oils and nuts) for animal fat (meat and dairy).\textsuperscript{168} Dietary trans FA increase TG levels minimally but should be avoided because they significantly raise LDL-C and lower HDL-C.\textsuperscript{169} Energy intake should be adjusted to achieve and maintain a healthy body weight.

The 2019 ESC/EAS guidelines for dyslipidaemia management recognize that ASCVD risk is increased at TG levels >1.7 mmol/L (>150 mg/dL), but only recommend initiating pharmacotherapy in high-risk patients if >2.3 mmol/L (>200 mg/dL) after excluding secondary causes.\textsuperscript{20} There are also no treatment goals, either for plasma TG or indices of remnant abundance, given limited evidence from randomized controlled trials that lowering TG or TRL reduce ASCVD risk.\textsuperscript{20} Thus, strategic approaches to lowering TRL warrant discussion. This point is especially pertinent given that PESA reported the presence of peripheral atherosclerotic plaques in 58% of middle-aged individuals with elevated TG levels (1.7 mmol/L), low-to-moderate cardiovascular risk, and high or normal LDL-C.\textsuperscript{38}

**Inhibiting lipoprotein production**

Inhibiting secretion of apoB-lipoproteins and apoB48-lipoproteins may be the optimal approach for achieving the reduction of all atherogenic lipoproteins. Drugs such as mipomersen [an antisense oligonucleotide (ASO) inhibitor of apoB translation] and lomitapide (an inhibitor of microsomal triglyceride transport protein activity) block either apoB synthesis or the addition of lipid during chylomicron and VLDL assembly in the intestine and liver, respectively. Both also promote hepatic TG accumulation and possible development of non-alcoholic fatty liver disease, limiting their use to severe hypercholesterolemia.\textsuperscript{170–173} Novel or combination therapies that inhibit the assembly of apoB-lipoproteins and protect against excess intracellular lipid by promoting FA oxidation or decreasing TG synthesis are, therefore, needed.

Reducing TG availability for VLDL assembly represents another approach. For example, high-dose omega-3 FA [3–4 g/day, usually the combination of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)] reduces VLDL–TG and apoB secretion by ~25–30%, with variable changes in fractional clearance rate.\textsuperscript{174,175} Some studies showed an increase in conversion of VLDL to IDL and LDL, although no change in plasma IDL and LDL levels. Thus, omega-3 FA may have limited impact on remnant populations or the total number of atherogenic lipoproteins. In REDUCE-IT (Reduction of Cardiovascular Events with EPA—Intervention Trial), high-dose EPA reduced
ASCVD risk, although it was suggested that only a modest part of this benefit was due to changes in TRL levels. The lack of benefit in STRENGTH (Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in High CV Risk Patients with Hypertriglyceridaemia) with a DHA/EPA combination suggests that DHA and EPA may differ in their effects on ASCVD.177

**Box 5** Approaches to assessment of atherosclerotic cardiovascular disease risk associated with triglyceride-rich lipoproteins and their remnants

| Index                  | Measurement                                                                 |
|------------------------|----------------------------------------------------------------------------|
| TG                     | • Fasting or non-fasting measurement                                       |
| Non-HDL-C              | • Directly measured total cholesterol minus HDL-C                           |
| TRL cholesterol        | • Direct assay, after isolation of the VLDL (density <1.006 g/mL) or VLDL + IDL (density <1.019 g/mL) fractions (Figure 1) |
|                        | • Estimated, multiply plasma TG by the ratio of cholesterol to TG in VLDL (relatively constant for fasting samples on a population basis, 0.46 mmol cholesterol/mmol TG or 0.2 mg/mg). Modifications are available for severe hypertriglyceridaemia or very low LDL-C levels 153,154 |
| Remnant particles      | • ‘Remnant-like particle’ assay, based on immunoaffinity separation of lipoprotein particles with the characteristics of chylomicron and VLDL remnants 158 |
|                        | • Direct assay, measuring cholesterol content in chylomicrons and VLDL and their remnants (including IDL), i.e. ‘TRL cholesterol’. This was developed with standardization against the equivalent ultracentrifugally isolated fraction (density<1.019 g/mL). TRL that are not remnants are also captured in this assay 159 |
| Emerging approaches    | Total apoB                                                                |
|                        | • With one copy of apoB, either apoB48 or apoB100, per particle of TRL and remnants, immunological assay of total apoB in the fraction comprising chylomicrons, VLDL, and remnants (density <1.019 g/mL) would provide a measure of total TRL (i.e. particle numbers of chylomicrons, VLDL and their remnants) |
|                        | • This assay could be refined by complementary estimation of intestinally derived apoB48- and liver-derived apoB100-containing particles |
|                        | • With standardization and clinical evaluation, the molar ratio of cholesterol/apoB in this fraction may indicate the degree of cholesteryl enrichment and, thus, remnant content and potential atherogenicity |
| Ceramide species       | • There is robust evidence for plasma ratios of ceramide species (e.g. [d18:1/16:0]/d18:1/24:0] as predictors of cardiovascular events and mortality |
|                        | • Given their lipotoxic properties and increased content in the TRL and remnant fraction (density <1.019 g/mL lipoproteins) in dyslipidaemic subjects, mass spectrometric assay of ceramides in this fraction may inform the putative atherogenicity of the lipidome of TRL and remnants 56,160–162 |

apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; IDL, intermediate-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; TG, triglyceride; TRL, triglyceride-rich lipoproteins; VLDL, very low-density lipoprotein.

**Reducing cholesteryl ester enrichment of remnants**

As CE transfer from HDL to TRL is a key step in remnant lipoprotein formation, inhibiting CETP should decrease remnants. Studies with evacetrapib or anacetrapib showed a marked decrease in the cholesterol/TG ratio in VLDL using measures that include remnants.178,179 While anacetrapib treatment led to a small risk reduction, putatively linked to a decrease in LDL-C, greater LDL-C reduction with evacetrapib did not confer cardiovascular benefit.180,181

**Stimulating lipolysis**

This approach lowers plasma TG in a range of patients, underlining the role of inefficient lipolysis in the aetiology of hypertriglyceridaemia (Figure 6). Fibrates are the archetypal agents, promoting lipolysis by increasing LpL activity 182 and decreasing the synthesis of apoCIII (Figure 4), thereby enhancing the efficiency of VLDL clearance. Whether stimulating lipolysis lowers remnant concentration and ASCVD risk depends on the efficiency of hepatic uptake pathways. It is equally uncertain as to whether more efficient lipolysis and increased conversion of remnants to LDL may be beneficial. Using a Mendelian randomization approach for LPL variants indicated that those associated with TG-lowering were linked to reductions in ASCVD.24 The LPLS447X variant that increases enzyme activity has also been linked to lower ASCVD.183

Outcomes trials with fibrates, other than gemfibrozil, failed to show clear evidence of reduction in cardiovascular events, although there was benefit in patient subgroups with raised TG with or without low HDL-C, patients who would be expected to have elevated remnant levels.184,185 Further insights are awaited from the PROMINENT trial, in which pemafibrate is being compared to placebo on a background of statin therapy.186

ApoCIII is a known inhibitor of LpL (Figure 4). Indeed, individuals with LOF APOC3 variants have low plasma TG levels 19,60,187 and
markedly increased in vivo fractional turnover of VLDL–TG with efficient conversion of VLDL apoB to LDL, indicating increased lipolysis.59,187 Of note, an ASO targeting APOC3 markedly reduced plasma TG levels in severe hypertriglyceridaemia, an effect equally evident in the absence of LpL activity.188,189

ANGPTL3 is another known inhibitor of LpL activity (Figure 4) and individuals with ANGPTL3 LOF variants have low levels of TG, LDL-C, and HDL-C.32,65 Effects on LDL-C, HDL-C, and apoB levels in hypertriglyceridaemic subjects have varied in early trials of a monoclonal antibody directed against ANGPTL3190 and an ASO therapy that reduced the synthesis of the protein.191 A single dose of an ANGPTL3 inhibitor reduced plasma TG levels ~40% in a patient deficient in APOC2; this effect persisted for 90 days, implying LpL-independent lowering of TG.192

Enhancing remnant clearance

Increasing the efficiency of removal pathways for atherogenic lipoproteins should, theoretically, reduce ASCVD risk. Statins up-regulate the LDL receptor and would be expected to decrease remnant particles by accelerating their catabolism.145,193 Statin-mediated TG-lowering is limited at optimal levels of TG (Box 1), but more effective at higher levels (>2.3 mmol/L), with similar percent reductions in TG and LDL-C.194 Statins also promote chylomicron remnant clearance and reduce lipaemia following a fat-rich meal.195 Thus, statins can reduce remnant abundance, providing further support for optimizing their use in individuals most at risk. However, stimulating receptor-mediated clearance alone is unlikely to address fully the residual remnant-associated risk of ASCVD.

PCSK9 inhibitors increase the activity of LDL receptors and the clearance rate of IDL in healthy subjects.196 Effects on VLDL clearance are less than with statins, with only modest TG lowering in hypertriglyceridaemia,197 implying a capacity to reduce plasma levels of smaller-sized remnants at lower TG levels, but not remnants at higher TG levels. PCSK9 inhibitors appear to have little effect on chylomicronaemia and apoB48 metabolism.198,199

As previously noted, apoCIII inhibits lipolysis and based on studies in rodents may also inhibit the hepatic uptake of remanent-like lipid emulsions.74,200,201 An ASO directed against apoCIII markedly reduced plasma TG levels in subjects lacking LpL activity,188,189 thus providing indirect support for improved hepatic uptake at low plasma apoCIII levels. In contrast, kinetic studies in humans with either complete60 or partial187 LOF of APOC2 showed markedly increased fractional clearance of VLDL–TG and apoB and increased conversion of VLDL to LDL without increased hepatic uptake of remnants. In a mouse model, the effect of reducing apoCIII on hepatic remnant removal was significant only when LpL activity was markedly reduced,202 possibly explaining the lack of apoB reduction with an apoCIII ASO in moderate hypertriglyceridaemia.203 These findings offer insights as to whether simply improving lipolysis—without increasing remnant removal—will reduce ASCVD risk in people with high TRL levels.

ANGPTL3, another confirmed inhibitor of LpL-mediated lipolysis, also appears to play a role in non-LpL-mediated clearance of TRL, as suggested by lowering of TG levels with ANGPTL3 inhibition in a patient lacking APOC2.192 Studies in mice also implicate a role for di-inhibited endothelial lipase in stimulating remnant removal by the liver, independent of the LDL receptor.76,203 Further support is provided by evidence that an ANGPTL3 monoclonal antibody increased the LDL fractional clearance rate and reduced plasma LDL-C and apoB levels in patients with homozygous familial hypercholesterolaemia.204,205

Consensus key points

- Regulation of plasma levels of TG, TRL, and remnants is complex. Developing therapeutics that reduce the levels of one or more of these lipoproteins and concomitantly reduce ASCVD risk is challenging.
- Improved understanding of the pathways that determine circulating levels of TG, TRL, and remnants is needed.
- A key question is whether targeting lipolysis and clearance of TRL and remnants rather than remnant production itself is more effective for reducing ASCVD risk.
- For existing therapies, clinical trials that use validated specific assays are essential to inform whether lowering levels of TG and TRL and/or remnants can reduce ASCVD risk.
- Determining the relative atherogenicity of TRL and remnants vs. LDL is critical and will require specific assays for these lipoprotein species.

Conclusions

Our knowledge of TG metabolism and the aberrations leading to elevated plasma TG levels is substantial. However, understanding the pathobiology of remnant lipoproteins (overviewed in the Graphical Abstract), the atherogenic potential of their lipidomic and proteomic composition, and their measurement is very much a ‘work-in-progress’ that is key to the development of optimal targeted therapies. This statement highlights two important unmet needs: (i) a standardized, readily applicable assay to measure remnants and (ii) therapeutic options to lower circulating levels of remnants to reduce residual ASCVD risk in patients on maximal LDL-C-lowering treatment. With several promising candidates, the answer will likely involve combination therapy targeting both remnant formation and clearance pathways and avoiding attendant increases in LDL particles. The latter is key, because any proatherogenic effects of TRL and remnants will be synergistic to those of other apoB-containing lipoproteins, particularly LDL and lipoprotein(a).17,25,93,104,206

Funding

The European Atherosclerosis Society Consensus Panel met at a closed expert meeting in London in January 2020 to critically appraise and discuss evidence relating to the definition, aetiology and metabolism of TRL and their remnants, their role in ASCVD, and clinical management. Logistic support for travel was provided by the Society. There were no other sources of funding.

Conflict of interest: Potential conflicts of interest outside the submitted work are summarized as follows. The following authors report receipt of grants, and/or personal honoraria for consultancy, lectures/speaker’s bureau from Abbott (L.S.T.); Acasti (D.G., R.A.H.); Actelion (L.S.T.); Aegerion (M.A., A.L.C., D.G., R.A.H.); Alkeza (J.B., M.J.C., D.G., G.F.L., B.G.N., M.R.T., A.T.H.); Akceia/Ionis (M.A., R.A.H., P.M.); Alexion (M.J.C.); Alfasigma (M.A.); Amgen (M.J.C.); Amgen (C.A.A.S., M.A., J.B.,
The data underlying this article will be shared on reasonable request.

Data availability

The data underlying this article will be shared on reasonable request.

References

1. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:12-14.
2. Chapman MJ, Ginsberg IH, Amanzour P, Andreotti F, Bornet J, Catapano AL, Despres JP, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Maslanz NA, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF. By intramural funds from the National Heart, Blood and Lung Institute.
3. Bjoernson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Soderlund S, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF, Wiklund O; for the European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in the American Heart Association.
4. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Ingelsson E, Kaptoge S, Ray KK, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
5. Mach F, Baigent C, Collins R, Thompson SG, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. Association of non-high-density lipoprotein cholesterol with cardiovascular disease: new insights from epidemiology, genetics, and biology. Eur Heart J 2016;37:2292–2333.
6. Hegele RA, Boren J, Ginsberg IH, Arca M, Avena M, Binder C, Catapano AL, Cibisova L, Chapman MJ, Cushman M, von Eckardstein A, Frikke-Schmidt R, Gaudet D, Hovingh GK, Kronenberg F, Luftjohann D, Parhofer KG, Parkhout RM, Tikkanen M, Taskinen MR, Tokgozoglu L, Taskinen MR, Tokgozoglu L, Wiklund O; Esc Scientific Document Group. 2016 European Atherosclerosis Society (EAS) and an Editorial Board Member, The European Heart Journal.

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

1. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:12-14.
2. Chapman MJ, Ginsberg IH, Amanzour P, Andreotti F, Bornet J, Catapano AL, Despres JP, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Maslanz NA, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF. By intramural funds from the National Heart, Blood and Lung Institute.
3. Bjoernson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Soderlund S, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF, Wiklund O; for the European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in the American Heart Association.
4. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Ingelsson E, Kaptoge S, Ray KK, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
5. Mach F, Baigent C, Collins R, Thompson SG, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. Association of non-high-density lipoprotein cholesterol with cardiovascular disease: new insights from epidemiology, genetics, and biology. Eur Heart J 2016;37:2292–2333.
6. Hegele RA, Boren J, Ginsberg IH, Arca M, Avena M, Binder C, Catapano AL, Cibisova L, Chapman MJ, Cushman M, von Eckardstein A, Frikke-Schmidt R, Gaudet D, Hovingh GK, Kronenberg F, Luftjohann D, Parhofer KG, Parkhout RM, Tikkanen M, Taskinen MR, Tokgozoglu L, Taskinen MR, Tokgozoglu L, Wiklund O; Esc Scientific Document Group. 2016 European Atherosclerosis Society (EAS) and an Editorial Board Member, The European Heart Journal.

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

1. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:12-14.
2. Chapman MJ, Ginsberg IH, Amanzour P, Andreotti F, Bornet J, Catapano AL, Despres JP, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Maslanz NA, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF. By intramural funds from the National Heart, Blood and Lung Institute.
3. Bjoernson E, Packard CJ, Adiels M, Andersson L, Matikainen N, Soderlund S, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF, Wiklund O; for the European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in the American Heart Association.
4. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Ingelsson E, Kaptoge S, Ray KK, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
5. Mach F, Baigent C, Collins R, Thompson SG, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. Association of non-high-density lipoprotein cholesterol with cardiovascular disease: new insights from epidemiology, genetics, and biology. Eur Heart J 2016;37:2292–2333.
6. Hegele RA, Boren J, Ginsberg IH, Arca M, Avena M, Binder C, Catapano AL, Cibisova L, Chapman MJ, Cushman M, von Eckardstein A, Frikke-Schmidt R, Gaudet D, Hovingh GK, Kronenberg F, Luftjohann D, Parhofer KG, Parkhout RM, Tikkanen M, Taskinen MR, Tokgozoglu L, Taskinen MR, Tokgozoglu L, Wiklund O; Esc Scientific Document Group. 2016 European Atherosclerosis Society (EAS) and an Editorial Board Member, The European Heart Journal.

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

References

1. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991;11:12-14.
2. Chapman MJ, Ginsberg IH, Amanzour P, Andreotti F, Bornet J, Catapano AL, Despres JP, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Maslanz NA, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjaerg-Hansen A, Watts GF. By intramural funds from the National Heart, Blood and Lung Institute.
triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. JAMA 2019;321:364–373.

27. Varbo A, Nordestgaard BG. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Ann Neurol 2019;85:530–559.

28. Kaltost A, Langsted A, Nordestgaard BG. Triglycerides and remnant cholestrol associated with risk of aortic valve stenosis: Mendelian randomization in the Copenhagen General Population Study. Eur Heart J 2020;41:2098–2102.

29. Do R, Stitziel NO, Won HH, Jorgensen AB, Duga S, Angelica Merlini P, Kiezen A, Farrell M, Goel A, Zuko C, Guilla I, Asletta R, Langane L, Pollo GM, Auer PL, NHLBI Exome Sequencing Project, Girelli D, Martinieli N, Farlow DN, DePristo MA, Roberts R, Stewart AF, Saleheen D, Danesh J, Epstein SE, Sivaphalaratnam S, Howling GK, Kastelein JJ, Samani NJ, Schunkert H, Demarchi H, Jankowski T, Warg J, Jorgensen FH, Hechter E, Muzu W, Kleber ME, Huang J, Johnson AD, Li M, Burke DL, Gross M, Liu Y, Amies Tt, Heiss G, Lange EM, Fusol AR, Taylor HA, Ohlivi O, Hatmesen A, Clark R, Reilly DF, Yin Y, Rivis MA, Donnelly P, Rossouw JF, Patsy BM, Herrington DM, Wilson JG, Rich SS, Bamshad M, Tracy RP, Cupples LA, Rader D, Myer MP, Rokshar J, Watkins K, Watson K, Atherley K, Asletta R, Saleheen D, Nelson J, Danesh J, Lander ES, Gabriel S, Saleheen D, Musunuru K, König IR, Webbe PE, Webb TR, Auer PL, Schick UM, Lu Y, Zhang H, Dube MP, Polin TI, Damcott CM, She H, Ott SH, Shelton J, Horenstein RB, Post W, McLennian JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR.

30. Jorgensen AB, Frykle-Schmidt R, Nordestgaard BG, Thyberg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. J Am Heart Assoc 2017;6:1134–1144.

31. Khera AV, Won HH, Pollo GM, O'Doherty DA, Li L, Liu Y, Stitziel NO, Natarajan P, Numara A, Emdin CA, Gupta N, Borecki IB, Asletta R, Duga S, Merlini PA, Correa A, Kessler T, Wilson JG, Bovorn MJ, Hall AS, Bradn PE, Sides DJ, Murray MP, Kirchner HL, Leader JB, Lavag DR, Mansu JN, Samani NJ, Schunkert H, Marrugat J, Elsoua R, McPherson R, Farrall M, Watson S, Lander ES, Rader DJ, Fauchier L, Sivapalaratnam S, Hout CV, Habegger L, Buckler D, Lia KM, Leader JB, Murray MF, Ritchie MD, Shaffer CM, El-Mokhtari NE, Franke A, Gottesman O, Heilmann S, Donnelly LA, Asselta R, Merlini PA, Duga S, Marzialino N, Denny JC, Goel A, Farrall M, Peloso GM, Won HH, Do R, van Iperen E, Kanoni S, Kruppa K, König IR, Weeke PE, Webb TR, Auer PL, Schick UM, Lu Y, Zhang H, Dube MP, Pollin TI, Damcott CM, She H, Ott SH, Shelton J, Horenstein RB, Post W, McLennian JC, Bielak LF, Peyser PA, Mitchell BD, Miller M, O'Connell JR.
4806b

H.N. Ginsberg et al.
98. Parks JS, Chung S, Shelnaz GS. Hepatic ABC transporters and triglyceride metabolism. Curr Opin Lipidol. 2012;23:196–200.

99. Stählin M, Fagerberg B, Adels M, Eklous K, Chapman MJ, Kontush A, Born J. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIAHA cohort: impact on small HDL particles. Biochim Biophys Acta 2013;1831:1056–1067.

100. Davidson P, Hultie J, Fagerberg B, Carnejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol. 2010;30:156–163.

101. Kontush A, Chapman MJ. Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 2008;8:51–59.

102. Renton RP, Brewer Jr. JB, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, Katusa J. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol 2013;10:48–60.

103. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89:331–340.

104. Ferencz BA, Ginsburg HH, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Born J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG. J Am Coll Cardiol 2011;58:132–139.

105. Nakajima K, Takana A. Atherogenic postprandial remnant lipoproteins: VLDL remnants as a causal factor in atherosclerosis. Clin Chim Acta 2020;433:313–319.

106. Schwartz EA, Reaven PD. Lipolysis of triglyceride-rich lipoproteins, vascular inflammation, and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol. 2010;30:156–163.

107. Ting HJ, Stice JP, Schaff UY, Hui DY, Rutledge JC, Knowlton AA, Passerini AG, Marz W, Bo¨hm M, Jankowski J, Kopf M, Latz E, Niemeyer BA, Fliser D, Laufs U. Atherosclerosis: Thromb Vasc Biol 2013;33:1423–1431.

108. Sandesara PB, Virani SS, Fazio S, Shapiro MD. The forgotten lipids: triglycerides, cholesterol, and inflammation in the arterial intima of genetically hyperlipidemic rabbits in vivo. J Lipid Res 2012;53:534–542.

109. Bjo¨rkegren J, Karpe F, Milne RW, Hamsten A. Differences in apolipoprotein and apolipoprotein-B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arterioscler Thromb Vasc Biol 2004;24:2162–2167.

110. Nakajima K, Nakano T, Tokita Y, Yatsuzuka S, Shimomura Y, Bals R, Kostner G, Jahnen-Dechent W, Menger MD, Rohrer L, Aßmann G, Pape S, Paschen A, Herter T, Schuster S, Silbernagel G, Sester M, Sester U, Oo ¨rni K. Extracellular lipids accumulate in human carotid arteries as distinct three-dimensional structures and have proinflammatory properties. Am J Pathol 2018;188:525–538.

111. Jin X, Dimitriadis EK, Liu Y, Combos CA, Chang J, Varsano N, Stempinski E, Fliser D, Jackson SN, Aßmann G, Woods AS, Addadi L, Kruth HS. Macrophages shed unique cholesterol in unique extracellular structures containing cholesterol microdomains. Arterioscler Thromb Vasc Biol. 2018;38:1504–1518.

112. Baumber M, Vehta MN, Dey AK, Powell-Wiley TM, Boissier WA. Cholesterol crystals and artherosclerosis. Eur Heart J 2020;41:2236–2239.

113. Tangirala RK, Jerome WG, Jones NL, Small DM, Johnson WJ, Glick JM, Mahlab FH, Rathschild GH. Formation of cholesterol monohydrate crystals in macrophage-derived foam cells. J Lipid Res 1994;35:93–104.

114. Duewell P, Kono H, Rayner KJ, Siros CM, Vladimer G, Bauersiefen FG, Abel GS, Franch L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock L, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for arteriosclerosis and activated by cholesterol crystals. Nature 2010;464:1357–1361.

115. Järvinen K, Lappalainen J, Oöni K, Viineik Ä, Matikainen S, Kovanen PT, Eklund KK. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010;5(11):e17165.

116. Beng T, Phillips JE, Mason RP, Cassells SW. Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture. Biochim Biophys Acta 2003;1645:1485–1492.

117. Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ. Cholesterol crystals associate with coronary plaque vulnerability in vivo. J Am Coll Cardiol 2015;65:630–632.

118. Shi X, Cai H, Wang F, Liu R, Xu X, Li M, Han Y, Yin Q, Ye R, Liu X. Cholesterol crystals are associated with carotid plaque vulnerability: an optical coherence tomography study. J Stroke Cerebrovas Dis 2020;29:105479.

119. Pourcet B, Staels B. Alternative macrophages in atherosclerosis: not always protective. J Clin Invest 2018;128:910–912.

120. Liberal E, Dallegri F, Montecucco F, Carbone F. Pathophysiological relevance of macrophage subsets in atherosclerosis. Thromb Haemost 2017;117:17–28.

121. Mahley RW, Innerarity TL, Rall SC Jr, Weszbrager KH. Lipoproteins of special significance in atherosclerosis. Plast and Textile Revised by studies of type III hyperlipoproteinemia. Am Acad NY Sci 1985;454:209–201.

122. Varbo A, Benn M, Tybjerg-Hansen A, Nordestgaard BG. Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 2013;128:1298–1309.

123. Balling M, Langsted A, Dahlback B, Nordestgaard BG. A third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals. Atherosclerosis 2019;286:97–104.
144. Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia. Preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 2000;20:189–197.

145. Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Clasdale M. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional catabolic rate. Arterioscler Thromb Vasc Biol 2014;34:129–145.

146. Remaley AT, Otis JE. Methodological issues regarding “a third of nonfasting plasma cholesterol is in remnant lipoproteins: lipoprotein subclass profiling in 9293 individuals”. Atherosclerosis 2020;320:55–56.

147. Pal S, Semorine K, Watts GF, Mamo J. Identification of lipoproteins of intestinal origin in human atherosclerotic plaque. Clin Chem Lab Med 2003;41:792–795.

148. Rau JH, Leippe A, Hamilton RL, Corvass N, Chaurie A, Tweedie- Hardman J, Kotite L, Kunitake ST, Ravel RJ, Kane JP. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1994;14:1767–1774.

149. Moretton JR. Atherosclerosis and alimentary hyperlipemia. Science 1947;106:190–191.

150. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Science 1985;228:66–70.

151. Lichtenstein AH, Van Horn L. Very low fat diets. Circulation 1998;98:935–939.

152. Skulas-Ray AC, Wilson PW, Harris WS, Brinton EA, Kris-Etherton PM, Richter CK, Jacobson TA, Engler MB, Miller R, Robinson JG, Blum CB, Rodriguez-Leyva D, de Ferranti SD, Welty FK, American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Omega-3 fatty acids for the management of hypertriglyceridemia: a Science Advisory from the American Heart Association. Circulation 2019;140:673–691.

153. Rimm EB, Williams P, Fosher K, Crimiq M, Stomper MF. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999;319:1523–1528.

154. Sacks FM, Lichtenstein AH, Wu JHY, Appel LJ, Creager MA, Kris-Etherton PM, Miller M, Rimm EB, Rudel LL, Robinson JG, Stone NJ, Van Horn LV, American Heart Association. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation 2013;126:e21–e23.

155. Katan MB, Zock PL, Mensink RP. Trans fatty acids and their effects on lipoproteins in humans. Annu Rev Nutr 1995;15:473–493.

156. Plum J, Ralston SH, Partridge S, et al. A microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia. Curr Atheroscler Rep 2020:22:38.

157. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun J, Camarillo J, Cifuentes F, et al. A consensus statement on the management of hypertriglyceridemia in adults: recommendations of the National Lipid Association. J Clin Lipidol 2010;4:5–25.

158. Nakajima K, Saito T, Tamura A, Suzuki M, Nakano T, Adachi M, Tanaka A, Tada J, Moriyama H, Aoyagi K, Ota Y, et al. Literature review of the mechanism of action and effects of treatment of remnant lipoprotein cholesterol with mipomersen and its use in familial hypercholesterolemia. Expert Opin Pharmacother 2019;20:127–131.

159. Stefanucci C. Lomitapide—a microsomal triglyceride transfer protein inhibitor for homozygous familial hypercholesterolemia. Curr Atheroscler Rep 2020;22:38.

160. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Siess W, De Backer G, et al. Microsomal triglyceride transfer protein inhibitors for the treatment of familial hypercholesterolemia. J Am Coll Cardiol 2020;75:2725–2735.

161. Langlois MR. Sverdlov A. Low-HDL cholesterol or apoB: which to prefer as a target for the prevention of atherosclerotic cardiovascular disease? Curr Atheroscler Rep 2020;22:67.

162. Grundy SM, Stone NJ, Bailey AL, Beam C, Birkenfeld KE. Monocarboxylic acids as protagonists in vascular complications of diabetes. Front Cardiovasc Med 2020;7:110.

163. Whitman SC, Miller DB, Wolfe BM, Hegele RA, Huff MW. Uptake of type III hypertriglyceridemic VLDL by macrophages is enhanced by oxidation, especially after treatment of rabbit VLDL with copper. Arterioscler Thromb Vasc Biol 1997;17:1707–1715.

164. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.

165. Sampson M, Ling C, Sun Q, Harb R, Ashmag M, Warnick R, Sethi A, Fleming JK, Otvos JD, Meeusen JW, Delaney SR, Jaffe AS, Shamburek R, Amar M, Remaley AT. A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and/or hypertriglyceridemia. JAMA Cardiol 2020;5:450–458.

166. Balling M, Aafa S, Varbo A, Langsted A, Davey Smith G, Nordestgaard BG. VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins. J Am Coll Cardiol 2020;76:2725–2735.

167. Ginter MH. Changes in lipoprotein kinetics during therapy with fenofibrate and other fibrate acid derivatives. Am J Med 1987;83:66–70.

168. Shearer GC, Savinova OV, Harris WS. Fish oil—how does it reduce plasma triglycerides? Biosci Bioeharm 2012;18:843–851.

169. Oscarsson J, Hurt-Camejo E. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins. J Am Coll Cardiol 2020;76:2725–2735.
183. Rip J, Nierman MC, Rass CJ, Jukema JW, Hayden MR, Kastelein JJ, Stroes ES, Kuivenhoven JA. Lipoprotein lipase 5447X-a naturally occurring gain-of-function mutation. *Arterioscler Thromb Vasc Biol* 2006;26:1236–1245.

184. ACCORD Study Group; Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Freedwald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Golf DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1563–1574.

185. Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, Taskinen MR, Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Ahmad Z, Banerjee P, Hamon S, Chan K-C, Bouzelmat A, Sasiela WJ, Pordy R, Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett M, Wolska A, Burke FM, Escobar M, Walters L, Lalic D, Hegele RA, Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV. Function mutation.

186. Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg HD, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Golf DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* 2010;362:1563–1574.

187. Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A. Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetes* 2009;58:93–498.

188. Pradhan AD, Paynter NP, Everett BM, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM. Rationale and design of the Fenofibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. *Am Heart J* 2018;206:80–93.

189. Reyes-Soffer G, Satlayd C, Horenstein RB, Holleran S, Matveyenko A, Thomas T, Nandakumar R, Ngi C, Karmally W, Ginsberg HN, Ramakrishnan R, Pollin TI. Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism. *Arterioscler Thromb Vasc Biol* 2019;39:63–72.

190. Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, Geary RS, Baker BF, Graham MJ, Crooke RM, Witzum JL. Targeting APOC3 in the familial chylomicronemia syndrome. *N Engl J Med* 2014;371:2201–2206.

191. Witzum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, Yang Q, Hughes SG, Geary RS, Arca M, Stroes ESG, Bergeron J, Soran H, Civiera F, Hemphill L, Tsikmas L, Blom DJ, O’Dea L, Bruckert E. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. *N Engl J Med* 2019;381:531–542.

192. Ahmad Z, Banerjee P, Hamon S, Chan K-C, Bouzelmat A, Sasiela WJ, Pordy R, Meliss S, Darsky H, Gipe DA, Dunbar RL. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. *J Clin Lipidol* 2020;14:3936–3945.

193. Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, Hurh E, Kingsbury J, Bartlett M, Wolska A, Burke FM, Escobar M, Walters L, Lalic D, Hegele RA, Le NA, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV. Experimental therapeutics for challenging metabolic and lipoprotein levels and distribution in patients with type 2 diabetes mellitus. *Arterioscler Thromb Vasc Biol* 2021;41:962–975.

194. Quarford RH, Michalopoulous G, Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. *J Biol Chem* 1982;257:1462–1467.

195. Gordts PL, Noeck R, Son NH, Ramsb L, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullig AE, Graham MJ, Goldberg JI, Crooke RM, Witzum JL, Esko JD. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. *J Clin Invest* 2016;126:2855–2866.

196. Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, Geary RS, Hughes SG, Viney NJ, Graham MJ, Crooke RM, Witzum JL, Brunzell JD, Kastelein JJ. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. *N Engl J Med* 2015;373:438–447.

197. Wu L. Soundarapandian MM, Castrore AM, Rader DJ. LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase. *Circ Res* 2020;127:1112–1114.

198. Raal FJ, Rosenson RS, Reeskamp LF, Hovingh GK, Kastelein JJP, Rubba P, Ali S, Banere P, Chan KC, Gipe DA, Khilla N, Pordy R, Weinrich DM, Yancopoulos GD, Zhang Y, Gaudet D. ELIPSE HofFH Investigators. Evinacumab for homozygous familial hypercholesterolemia. *N Engl J Med* 2020;383:711–720.

199. Reeskamp LF, Miller JS, Wu L, Jansen H, van Harskamp D, Schierbeek H, Gipe DA, Rader DJ, Dallinga-Thie GM, Hovingh GK, Cuchel M. ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia. Brief Report. *Arterioscler Thromb Vasc Biol* 2021;41:1753–1759.

200. Nordestgaard BG, Chapman MJ, Reeskamp LF, Hovingh GK, Amarenco P, Catapano A, Desamps OS, Fisher E, Kovarn PEN, Kuivenhoven JA, Lensen P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tybjærg-Hansen A. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J* 2010;31:2844–2853.